BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) a medical technology company committed to delivering
unprecedented accuracy and precision to intracardiac signal
visualization, announced today that the U.S. Patent and Trademark
Office has awarded several new utility patents covering the
Company’s PURE EP™ digital signal processing technology.
Kenneth Londoner, Chairman and CEO of BioSig, commented, “We are
pleased to add five utility patent awards to our expanding
intellectual property portfolio of more than 100 patents and patent
applications in the U.S. and abroad. Our robust patent protection
and well-constructed claims cover BioSig’s first mover advantage
for our novel PURE EP™ Platform.”
New Patent Awards
U.S. Patent Application No. 16/543,061 was
allowed on September 22, 2023 and is entitled
“Systems and Methods To Display Cardiac
Signals Based on a Signal Pattern.” The
patent application describes and claims a computer method for
viewing cardiac signals side by side and vertically stacked on top
of each other as a pattern is matched to one of the cardiac
signals.
U.S. Patent No. 11,737,699 granted on
August 29, 2023 and is entitled
“Systems and Methods for Performing
Electrophysiology (EP) Signal
Processing.” The patent describes and
claims methods and systems for producing a clean unipolar
signal.
U.S. Patent No. 11,737,701 granted on
August 29, 2023 and is entitled
“Methods, Systems and Media For
Reconstructing Bioelectric Lead
Placement.” The patent describes and
claims methods and systems for reconstructing electrode placement
on a patient using artificial intelligence.
U.S. Patent 11,617,529 granted on April
4, 2023 and is entitled “Apparatus and Methods for
Removing a Large-Signal Voltage Offset from a Biomedical
Signal.” The patent claims a method for
processing an electrical signal having a large differential voltage
offset.
U.S. Patent 11,617,530 granted on April
4, 2023 and is entitled “Apparatus and Methods for
Removing a Large-Signal Voltage Offset from a Biomedical
Signal.” The patent claims a system for
the removal of noise in electrocardiogram (ECG) and intracardiac
(IC) signals.
BioSig’s Total Patent Portfolio
- 35 issued and allowed utility patents
- 30 issued worldwide design patents
- 23 U.S. and foreign utility patent applications pending
covering various aspects of the PURE EP Platform
- 1 allowed and 1 pending U.S. patent applications directed to
artificial intelligence (AI)
- Licenses to 11 patents and 9 additional worldwide utility
patent applications pending from Mayo Foundation for Medical
Education and Research
About The PURE EP™ PlatformThe PURE EP™
Platform serves physicians by enabling the real-time acquisition of
raw cardiac signal data—absent of unnecessary noise or interference
inherent in traditional approaches. By leveraging a
first-of-its-kind combination of hardware and software, the PURE
EP™ Platform is designed to deliver unprecedented intracardiac
signal purity that pushes the boundaries of cardiac arrhythmia
identification, diagnosis, and treatment.
In a blinded clinical study recently published in
the Journal of Cardiovascular Electrophysiology,
electrophysiologists rated PURE EP™ as superior to conventional
systems for 75.2% of signal samples, with 87% earning a rating of
equivalent or superior. Data presented at Heart Rhythm Society 2023
demonstrated the PURE EP™ Platform’s capacity to facilitate
ablations in a third of the usual time, reducing procedure time and
improving workflow efficiencies, without sacrificing accuracy,
precision, or efficacy.1
The PURE EP™ Platform is currently in a national commercial
launch and an integral part of well-respected healthcare systems,
including Mayo Clinic, Texas Cardiac Arrhythmia Institute,
Cleveland Clinic, and Kansas City Heart Rhythm Institute.
About BioSig Technologies, Inc.BioSig
Technologies is a medical technology company focused on
deciphering the body’s electrical signals, starting with heart
rhythms. By leveraging a first of its kind combination of hardware
and software, we deliver unprecedented cardiac signal clarity,
ending the reliance on ‘mixed signals’ and ‘reading between the
lines.’ Our platform technology is addressing some of healthcare’s
biggest challenges—saving time, saving costs, and saving lives.
The Company’s product, the PURE EP™ Platform, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform highly targeted
cardiac ablation procedures with increased procedural efficiency
and efficacy.
An estimated, 14.4 million Americans suffer from cardiac
arrhythmias, and the global EP market is projected to reach $16B in
2028 with an 11.2% growth rate.2
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 https://onlinelibrary.wiley.com/doi/10.1111/jce.15250
2 Global Market Insights, Inc. (2022, March)
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024